FINWIRES · TerminalLIVE
FINWIRES

Mizuho Initiates Zentalis Pharmaceuticals at Outperform With $8 Price Target

By

Zentalis Pharmaceuticals (ZNTL) has an average rating of overweight and mean price target of $6.50, according to analysts polled by FactSet.

(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)

Related Articles